Sumitomo Mitsui DS Asset Management Company Ltd Acquires 1,317 Shares of Natera, Inc. $NTRA

Sumitomo Mitsui DS Asset Management Company Ltd increased its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 10.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 14,324 shares of the medical research company’s stock after purchasing an additional 1,317 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Natera were worth $5,920,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in NTRA. BlackRock Inc. bought a new position in shares of Natera during the 2nd quarter worth approximately $2,962,770,000. Arrowstreet Capital Limited Partnership grew its position in shares of Natera by 1.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,191,732 shares of the medical research company’s stock worth $238,334,000 after buying an additional 11,793 shares during the period. Maverick Capital Ltd. grew its position in shares of Natera by 24.1% during the 1st quarter. Maverick Capital Ltd. now owns 1,171,633 shares of the medical research company’s stock worth $234,315,000 after buying an additional 227,605 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Natera by 10.7% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 833,376 shares of the medical research company’s stock worth $226,220,000 after buying an additional 80,440 shares during the period. Finally, Bank of America Corp DE bought a new stake in shares of Natera in the 2nd quarter valued at $199,960,000. 99.90% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Natera

In related news, CEO Steven Chapman sold 1,273 shares of the firm’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $413.31, for a total value of $526,143.63. Following the transaction, the chief executive officer owned 96,926 shares of the company’s stock, valued at approximately $40,060,485.06. This trade represents a 1.30% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $414.22, for a total value of $1,242,660.00. Following the transaction, the insider owned 106,914 shares of the company’s stock, valued at $44,285,917.08. This trade represents a 2.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 52,985 shares of company stock worth $16,119,137. 5.05% of the stock is currently owned by insiders.

Natera Trading Up 1.8%

NTRA opened at $413.38 on Thursday. The company’s fifty day moving average price is $363.64 and its two-hundred day moving average price is $280.16. Natera, Inc. has a 1-year low of $181.00 and a 1-year high of $437.41. The company has a market cap of $59.59 billion, a price-to-earnings ratio of -303.95 and a beta of 1.50.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. The firm had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The business’s quarterly revenue was up 37.7% compared to the same quarter last year. During the same period last year, the firm earned ($0.74) earnings per share. As a group, equities analysts forecast that Natera, Inc. will post -1.05 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on NTRA shares. Piper Sandler boosted their target price on shares of Natera from $249.00 to $363.50 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Zacks Research lowered shares of Natera from a “hold” rating to a “strong sell” rating in a research note on Friday, October 16th. Citigroup raised their price target on shares of Natera from $365.00 to $480.00 and gave the stock a “buy” rating in a report on Tuesday, October 6th. Canaccord Genuity Group raised their price target on shares of Natera from $375.00 to $500.00 and gave the stock a “buy” rating in a report on Monday. Finally, Sanford C. Bernstein started coverage on shares of Natera in a research note on Friday, June 26th. They issued an “outperform” rating and a $310.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $374.64.

Natera Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.